dc.contributor.author
Strašek Benedik, Nika
dc.contributor.author
Talagayev, Valerij
dc.contributor.author
Matziol, Troy
dc.contributor.author
Dolšak, Ana
dc.contributor.author
Sosič, Izidor
dc.contributor.author
Weindl, Günther
dc.contributor.author
Wolber, Gerhard
dc.contributor.author
Sova, Matej
dc.date.accessioned
2025-09-08T11:26:21Z
dc.date.available
2025-09-08T11:26:21Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/49157
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-48880
dc.description.abstract
Toll-like receptors (TLRs) are essential for the innate immune system as they recognize pathogen-associated molecular patterns and trigger immune responses. Overactivation of TLR8 by endogenous nucleic acids is associated with the development of autoimmune diseases and promotes inflammatory responses. This study presents the design, synthesis, and evaluation of a series of TLR8 antagonists based on the optimization of previously reported 6-(trifluoromethyl)pyrimidin-2-amines, with targeted modifications to further explore structure-activity relationships (SAR) and increase potency. A two-step synthesis involving nucleophilic aromatic substitution and Suzuki coupling was used to prepare two series of new compounds. The biological evaluation revealed that compounds 14 and 26 exhibited promising TLR8 antagonistic activity with IC50 values of 6.5 and 8.7 μmol L–1, respectively. Compound 14 showed reduced cell viability at higher concentrations, while compound 26 showed no cytotoxic effects, making it a promising candidate for further investigation.
en
dc.format.extent
25 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
Toll-like receptors
en
dc.subject
TLR8 antagonists
en
dc.subject
autoimmune disorders
en
dc.subject
immunomodulation
en
dc.subject.ddc
500 Naturwissenschaften und Mathematik::540 Chemie::540 Chemie und zugeordnete Wissenschaften
dc.title
Optimization of 6-(trifluoromethyl)pyrimidine derivatives as TLR8 antagonists
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.2478/acph-2025-0011
dcterms.bibliographicCitation.journaltitle
Acta Pharmaceutica
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.pagestart
159
dcterms.bibliographicCitation.pageend
183
dcterms.bibliographicCitation.volume
75
dcterms.bibliographicCitation.url
https://doi.org/10.2478/acph-2025-0011
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie

refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1846-9558
refubium.resourceType.provider
WoS-Alert